Cerecor signs deal with Merck for potential CNS drugs

Baltimore-based biotech firm Cerecor secured exclusive global rights to develop and market compounds that inhibit catechol-O-methyltransferase from Merck & Co. Cerecor said the agents have the potential to be used as treatments for addiction, schizophrenia and other central nervous system disorders. Cerecor will review more than 2,000 drug candidates and select some for clinical development. Merck could get milestone fees and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN